BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29163797)

  • 1. PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients.
    Sznurkowski JJ; Żawrocki A; Sznurkowska K; Pęksa R; Biernat W
    Oncotarget; 2017 Oct; 8(52):89903-89912. PubMed ID: 29163797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local immune response depends on p16INK4a status of primary tumor in vulvar squamous cell carcinoma.
    Sznurkowski JJ; Żawrocki A; Biernat W
    Oncotarget; 2017 Jul; 8(28):46204-46210. PubMed ID: 28515351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated model for prognosis in vulvar squamous cell carcinoma.
    Zhang T; Zhu Y; Luo J; Li J; Niu S; Chen H; Zhou F
    BMC Cancer; 2023 Jun; 23(1):534. PubMed ID: 37308869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
    Hu C; Tian S; Lin L; Zhang J; Ding H
    Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance and significance of programmed death-ligand 1 expression, tumor-infiltrating lymphocytes, and p16 status in sinonasal squamous cell carcinoma.
    Quan H; Yan L; Wang S; Wang S
    Cancer Manag Res; 2019; 11():4335-4345. PubMed ID: 31190998
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy.
    Kortekaas KE; Santegoets SJ; Tas L; Ehsan I; Charoentong P; van Doorn HC; van Poelgeest MIE; Mustafa DAM; van der Burg SH
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34716208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
    Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
    Front Immunol; 2021; 12():798424. PubMed ID: 35145511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
    Schoenfeld JD; Gjini E; Rodig SJ; Tishler RB; Rawal B; Catalano PJ; Uppaluri R; Haddad RI; Hanna GJ; Chau NG; Rabinowits G; Lorch J; Jo VY; Krane JF; Goguen LA; Annino DJ; Abdelrahman S; Lipschitz M; Margalit DN
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):137-145. PubMed ID: 29960819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
    Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
    BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The overexpression of p16 is not a surrogate marker for high-risk human papilloma virus genotypes and predicts clinical outcomes for vulvar cancer.
    Sznurkowski JJ; Żawrocki A; Biernat W
    BMC Cancer; 2016 Jul; 16():465. PubMed ID: 27411473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung.
    Ohtaki Y; Kaira K; Atsumi J; Nagashima T; Kawashima O; Ibe T; Kamiyoshihara M; Onozato R; Fujita A; Yazawa T; Sugano M; Iijima M; Nakazawa S; Obayashi K; Kosaka T; Yajima T; Kuwano H; Shirabe K; Mogi A; Shimizu K
    Am J Transl Res; 2018; 10(10):3243-3253. PubMed ID: 30416665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma.
    Cocks M; Chaux A; Jenson EG; Miller JA; Rodriguez Pena MDC; Tregnago AC; Taheri D; Eich ML; Sharma R; Vang R; Netto GJ
    Virchows Arch; 2020 Jul; 477(1):93-102. PubMed ID: 31993774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
    Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
    Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression and immune cells infiltration in primary tracheobronchial neoplasm.
    Zheng KF; Liu YJ; Ma N; Xiong YL; Tang XY; Zhang Q; Luo ZL; Tian HH; Hofman P; Ichiki Y; Metro G; Tachihara M; Gong L; Li XF; Zhao JB
    Transl Lung Cancer Res; 2021 Dec; 10(12):4617-4630. PubMed ID: 35070765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
    Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
    Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.
    Kortekaas KE; Santegoets SJ; Abdulrahman Z; van Ham VJ; van der Tol M; Ehsan I; van Doorn HC; Bosse T; van Poelgeest MIE; van der Burg SH
    J Immunother Cancer; 2019 Sep; 7(1):236. PubMed ID: 31481117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC.
    Edlund K; Madjar K; Mattsson JSM; Djureinovic D; Lindskog C; Brunnström H; Koyi H; Brandén E; Jirström K; Pontén F; Rahnenführer J; Micke P; Hengstler JG
    J Thorac Oncol; 2019 Apr; 14(4):628-640. PubMed ID: 30639618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma.
    Kim HS; Lee JY; Lim SH; Park K; Sun JM; Ko YH; Baek CH; Son YI; Jeong HS; Ahn YC; Lee MY; Hong M; Ahn MJ
    Cancer Res Treat; 2016 Apr; 48(2):527-36. PubMed ID: 26511814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of HPV status and PD-L1 expression in prognosis of laryngeal squamous cell carcinoma.
    Yang SM; Wu M; Han FY; Sun YM; Yang JQ; Liu HX
    Int J Clin Exp Pathol; 2021; 14(1):107-115. PubMed ID: 33532028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.